Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

HIV-1 drug resistance in antiretroviral-naive individuals with HIV-1-associated tuberculous meningitis initiating antiretroviral therapy in Vietnam.

Thao VP, Le T, Török EM, Yen NT, Chau TT, Jurriaans S, van Doorn HR, de Jong MD, Farrar JJ, Dunstan SJ.

Antivir Ther. 2012;17(5):905-13. doi: 10.3851/IMP2092. Epub 2012 Mar 21. Erratum in: Antivir Ther. 2012;17(5):937. van Doorn, Rogier H [corrected to van Doorn, H Rogier].

PMID:
22473024
2.

Low prevalence of transmitted drug resistance of HIV-1 during 2008-2012 antiretroviral therapy scaling up in Southern Vietnam.

Tanuma J, Quang VM, Hachiya A, Joya A, Watanabe K, Gatanaga H, Van Vinh Chau N, Chinh NT, Oka S.

J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):358-64. doi: 10.1097/QAI.0000000000000196.

PMID:
24815852
3.

HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.

Pham QD, Huynh TK, Luong TT, Tran T, Vu TX, Truong LX.

HIV Clin Trials. 2013 Jan-Feb;14(1):34-44. doi: 10.1410/hct1401-34.

PMID:
23372113
4.
5.

Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran.

Memarnejadian A, Menbari S, Mansouri SA, Sadeghi L, Vahabpour R, Aghasadeghi MR, Mostafavi E, Abdi M.

PLoS One. 2015 May 11;10(5):e0126955. doi: 10.1371/journal.pone.0126955. eCollection 2015.

6.

HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.

Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, Botes ME, Wellington M, Osibogun A, Sigaloff KC, Nankya I, Schuurman R, Wit FW, Stevens WS, van Vugt M, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER).

Lancet Infect Dis. 2011 Oct;11(10):750-9. doi: 10.1016/S1473-3099(11)70149-9. Epub 2011 Jul 27.

PMID:
21802367
7.

Genetic Diversity and Drug Resistance Among Antiretroviral Treatment-Failed Individuals from 2010 to 2012 in Honghe, China.

Yang C, Yang S, Li J, Yang B, Liu J, Li H, Bian Z.

AIDS Res Hum Retroviruses. 2015 Aug;31(8):822-9. doi: 10.1089/AID.2014.0348. Epub 2015 Jul 16.

PMID:
25919896
8.

Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil.

Cerqueira DM, Amorim RM, Silva RR, Camara GN, Brígido MM, Martins CR.

Mem Inst Oswaldo Cruz. 2004 Dec;99(8):877-82. Epub 2005 Mar 4.

9.

Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.

Svärd J, Mugusi S, Mloka D, Neogi U, Meini G, Mugusi F, Incardona F, Zazzi M, Sönnerborg A.

PLoS One. 2017 Jun 5;12(6):e0178942. doi: 10.1371/journal.pone.0178942. eCollection 2017.

10.

Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China.

Li H, Zhong M, Guo W, Zhuang D, Li L, Liu Y, Bao Z, Liu S, Wang X, Li T, Yang S, Li J.

PLoS One. 2013 Aug 29;8(8):e72630. doi: 10.1371/journal.pone.0072630. eCollection 2013.

11.

Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.

Mulu A, Maier M, Liebert UG.

PLoS One. 2015 Oct 29;10(10):e0141318. doi: 10.1371/journal.pone.0141318. eCollection 2015.

12.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
13.

Screening for antiretroviral drug resistance among treatment-naive human immunodeficiency virus type 1-infected individuals in Lebanon.

Mokhbat JM, Melhem NM, El-Khatib Z, Zalloua P.

J Infect Dev Ctries. 2014 Mar 13;8(3):339-48. doi: 10.3855/jidc.3593.

14.

HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients.

Elmi Abar A, Jlizi A, Darar HY, Kacem MA, Slim A.

Diagn Pathol. 2012 Oct 8;7:138. doi: 10.1186/1746-1596-7-138.

15.

Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.

Onywera H, Maman D, Inzaule S, Auma E, Were K, Fredrick H, Owiti P, Opollo V, Etard JF, Mukui I, Kim AA, Zeh C.

PLoS One. 2017 Feb 8;12(2):e0171124. doi: 10.1371/journal.pone.0171124. eCollection 2017.

16.

Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.

Nanfack AJ, Redd AD, Bimela JS, Ncham G, Achem E, Banin AN, Kirkpatrick AR, Porcella SF, Agyingi LA, Meli J, Colizzi V, Nádas A, Gorny MK, Nyambi PN, Quinn TC, Duerr R.

J Clin Microbiol. 2017 Sep;55(9):2785-2800. doi: 10.1128/JCM.00634-17. Epub 2017 Jun 28.

17.

Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.

Aghokeng AF, Kouanfack C, Laurent C, Ebong E, Atem-Tambe A, Butel C, Montavon C, Mpoudi-Ngole E, Delaporte E, Peeters M.

AIDS. 2011 Nov 13;25(17):2183-8. doi: 10.1097/QAD.0b013e32834bbbe9.

PMID:
21860346
18.

Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.

de Mulder M, Yebra G, Martín L, Prieto L, Mellado MJ, Rojo P, Muñoz-Fernández MÁ, Jiménez de Ory S, Ramos JT, Holguín A; Madrid cohort of HIV-infected children.

J Antimicrob Chemother. 2011 Oct;66(10):2362-71. doi: 10.1093/jac/dkr305. Epub 2011 Aug 2.

PMID:
21810838
19.

Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.

Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, Rinke de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Ng KP, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HM, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW.

PLoS Med. 2015 Apr 7;12(4):e1001810. doi: 10.1371/journal.pmed.1001810. eCollection 2015 Apr. Erratum in: PLoS Med. 2015 Jun;12(6):e1001845.

20.

Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.

Boender TS, Kityo CM, Boerma RS, Hamers RL, Ondoa P, Wellington M, Siwale M, Nankya I, Kaudha E, Akanmu AS, Botes ME, Steegen K, Calis JC, Rinke de Wit TF, Sigaloff KC.

J Antimicrob Chemother. 2016 Oct;71(10):2918-27. doi: 10.1093/jac/dkw218. Epub 2016 Jun 23.

PMID:
27342546

Supplemental Content

Support Center